Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQ4N with Radiation and Temozolomide in Newly Diagnosed Glioblastoma
NCT00394628Phase 2Unknown
- Sponsor
- Novacea
- Start
- Oct 2006
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of banoxantrone in glioblastoma multiforme (GBM), sponsored by Novacea. Primary endpoints: Evaluation of the safety and tolerability of AQ4N in combination with radiation therapy and temozolomide and Rate of progression-free survival at 6 months. Status: unknown.
02
Drugs
banoxantrone
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00394628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00394628.